VAS 2381
Alternative Names: VAS-2381Latest Information Update: 19 Sep 2005
At a glance
- Originator vasopharm BIOTECH
- Class Vasoprotectives
- Mechanism of Action Nitric oxide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cerebral ischaemia
Most Recent Events
- 05 Aug 2005 Discontinued - Preclinical for Cerebral ischaemia in Germany (unspecified route)
- 21 Aug 2003 Preclinical trials in Cerebral ischaemia in Germany (unspecified route)